{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:18:19Z","timestamp":1768875499296,"version":"3.49.0"},"reference-count":76,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most frequently found primary malignancy of the liver, showing an accelerated upward trend over the past few years and exhibiting an increasing relationship with metabolic syndrome, obesity, dyslipidemia and type 2 diabetes mellitus. The connection between these risk factors and the occurrence of HCC is represented by the occurrence of non-alcoholic fatty liver disease (NAFLD) which later, based on genetic predisposition and various triggers (including the presence of chronic inflammation and changes in the intestinal microbiome), may evolve into HCC. HCC in many cases is diagnosed at an advanced stage and can be an incidental finding. We present such a scenario in the case of a 41-year-old male patient who had mild obesity and mixed dyslipidemia, no family or personal records of digestive pathologies and who recently developed a history of progressive fatigue, dyspepsia and mild upper abdominal discomfort initially thought to be linked to post-COVID syndrome, as the patient had COVID-19 pneumonia a month prior. The abdominal ultrasound revealed a mild hepatomegaly with bright liver aspect of the right lobe (diffuse steatosis), a large zone of focal steatosis (segments IV, III and II) and a left lobe tumoral mass, highly suggestive of malignancy. Point shear wave elastography at the right lobe ruled out an end-stage chronic liver disease. Additional laboratory investigations, imaging studies (magnetic resonance imaging) and histopathological examination of liver fragments confirmed a highly aggressive HCC, with poorly differentiation-G3, (T4, N 1M 0) and stage IVA, associated with nonalcoholic steatohepatitis (NASH). A sorafenib course of treatment was attempted, but the patient discontinued it due to severe side effects. The subsequent evolution was extremely unfavorable, with rapid degradation, a few episodes of upper digestive bleeding, hepatic insufficiency and mortality in a couple of months. Conclusions: Diagnosis of NASH-related HCC is either an accidental finding or is diagnosed at an advanced stage. In order to earn time for a proper treatment, it becomes important to diagnose it at an early stage, for which regular check-ups should be performed in groups having the risk factors related to it. Patients suffering from obesity and mixed dyslipidemia should undergo periodic abdominal ultrasound examinations. This should be emphasized even more in the cases showing NASH. Complaints of any kind post-COVID-19 should be dealt with keenly as little is yet known about its virulence and its long-term side effects.<\/jats:p>","DOI":"10.3390\/life14010025","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T20:44:15Z","timestamp":1703450655000},"page":"25","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["NASH\/NAFLD-Related Hepatocellular Carcinoma: An Added Burden"],"prefix":"10.3390","volume":"14","author":[{"given":"Doina","family":"Georgescu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I\u2014Medical Semiotics I, Centre for Advanced Research in Cardiovascular Diseases and Hemostaseology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lighezan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I\u2014Medical Semiotics I, Centre for Advanced Research in Cardiovascular Diseases and Hemostaseology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-0479","authenticated-orcid":false,"given":"Ciprian","family":"Rosca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I\u2014Medical Semiotics I, Centre for Advanced Research in Cardiovascular Diseases and Hemostaseology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daciana","family":"Nistor","sequence":"additional","affiliation":[{"name":"Department of Functional Sciences, Physiology, Centre of Imuno-Physiology and Biotechnologies (CIFBIOTEH), \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"},{"name":"Centre for Gene and Cellular Therapies in Cancer, 3000723 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-7664","authenticated-orcid":false,"given":"Oana","family":"Ancusa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I\u2014Medical Semiotics I, Centre for Advanced Research in Cardiovascular Diseases and Hemostaseology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Suceava","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I\u2014Medical Semiotics I, Centre for Advanced Research in Cardiovascular Diseases and Hemostaseology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-878X","authenticated-orcid":false,"given":"Mihaela","family":"Iancu","sequence":"additional","affiliation":[{"name":"Department 5, Carol Davila University of Medicine and Pharmacy, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-7182","authenticated-orcid":false,"given":"Nilima","family":"Kundnani","sequence":"additional","affiliation":[{"name":"Department of Cardiology\u2014Discipline of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Research Centre of Timisoara Institute of Cardiovascular Diseases, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: Consider the population","volume":"47","author":"Mittal","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and Management of Hepatocellular Carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e7492","DOI":"10.1136\/bmj.e7492","article-title":"Dietary sugars and body weight: Systematic review and meta-analyses of randomised controlled trials and cohort studies","volume":"346","author":"Mallard","year":"2012","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e013543","DOI":"10.1136\/bmjopen-2016-013543","article-title":"Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: A microsimulation model","volume":"7","author":"Vreman","year":"2017","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1161\/CIRCULATIONAHA.118.036751","article-title":"Cost-Effectiveness of the US Food and Drug Administration Added Sugar Labeling Policy for Improving Diet and Health","volume":"139","author":"Huang","year":"2019","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nier, A., Brandt, A., Conzelmann, I.B., \u00d6zel, Y., and Bergheim, I. (2018). Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern. Nutrients, 10.","DOI":"10.3390\/nu10091329"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.jhepr.2023.100811","article-title":"Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma","volume":"5","author":"Talamantes","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1634\/theoncologist.2012-0066","article-title":"Body mass index and risk of primary liver cancer: A meta-analysis of prospective studies","volume":"17","author":"Wang","year":"2012","journal-title":"Oncologist"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/COC.0000000000000388","article-title":"Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis","volume":"41","author":"Gupta","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12072-015-9679-0","article-title":"Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis","volume":"10","author":"Mohamad","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_14","first-page":"57","article-title":"New insights on hepatocellular carcinoma: Epidemiology and clinical aspects","volume":"4","author":"Claudio","year":"2018","journal-title":"New Insights Hepatocell. Carcinoma Epidemiol. Clin. Asp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijmr.IJMR_1456_17","article-title":"Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern","volume":"149","author":"Dhamija","year":"2019","journal-title":"Indian J. Med. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s12276-020-00527-1","article-title":"Hepatocellular carcinoma: Old friends and new tricks","volume":"52","author":"Kim","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/hep.29660","article-title":"Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies","volume":"67","author":"Simon","year":"2018","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q.M., and Hanratty, B. (2020). Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003100"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.27016","article-title":"Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer","volume":"60","author":"Aleksandrova","year":"2014","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2264737","DOI":"10.1155\/2021\/2264737","article-title":"Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota\/FXR\/FGF15 Signaling Pathway","volume":"2021","author":"Luo","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e01155-21","DOI":"10.1128\/mBio.01155-21","article-title":"Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice","volume":"12","author":"Matsui","year":"2021","journal-title":"mBio"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1021\/acs.jafc.2c04817","article-title":"Nuciferine Protects Against High-Fat Diet-Induced Hepatic Steatosis via Modulation of Gut Microbiota and Bile Acid Metabolism in Rats","volume":"70","author":"Sun","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115333","DOI":"10.1016\/j.jep.2022.115333","article-title":"Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice","volume":"294","author":"Li","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhong, L., Lyu, W., Lin, Z., Lu, J., Geng, Y., Song, L., and Zhang, H. (2023). Quinoa Ameliorates Hepatic Steatosis, Oxidative Stress, Inflammation and Regulates the Gut Microbiota in Nonalcoholic Fatty Liver Disease Rats. Foods, 12.","DOI":"10.3390\/foods12091780"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: Current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/liv.13031","article-title":"The story of HCC in NAFLD: From epidemiology, across pathogenesis, to prevention and treatment","volume":"36","author":"Margini","year":"2016","journal-title":"Liver Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tang, S., Zhang, J., Mei, T.T., Guo, H.Q., Wei, X.H., Zhang, W.Y., Liu, Y.L., Liang, S., Fan, Z.P., and Ma, L.X. (2019). Association of TM6SF2 rs58542926 T\/C gene polymorphism with hepatocellular carcinoma: A meta-analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6173-4"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00535-015-1116-6","article-title":"The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus","volume":"51","author":"Ueyama","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ccr.2013.11.005","article-title":"NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma","volume":"24","author":"Gao","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: From new variants to the clinic","volume":"72","author":"Valenti","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/liv.13972","article-title":"Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease","volume":"39","author":"Pelusi","year":"2019","journal-title":"Liver Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population","volume":"72","author":"Richardson","year":"2020","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease","volume":"378","author":"Cheng","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3889\/oamjms.2015.111","article-title":"Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment","volume":"3","author":"Janevska","year":"2015","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4254\/wjh.v9.i11.533","article-title":"Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management","volume":"9","author":"Cholankeril","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/liv.12903","article-title":"Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma","volume":"35","author":"Chettouh","year":"2015","journal-title":"Liver Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Li, S., Saviano, A., Erstad, D.J., Hoshida, Y., Fuchs, B.C., Baumert, T., and Tanabe, K.K. (2020). Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123817"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12325-018-0673-5","article-title":"A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies","volume":"35","author":"Vicario","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.37358\/RC.19.10.7611","article-title":"Chronic Pelvic Pain and Irritable Bowel Syndrome: Is Subclinical Inflammation Bridging the Gap?","volume":"70","author":"Georgescu","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3389\/fphar.2018.01082","article-title":"The Role of Gut Microbiota in Atherosclerosis and Hypertension","volume":"9","author":"Ma","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Georgescu, D., Iurciuc, M.S., Ionita, I., Dragan, S., Muntean, M., Ancusa, O.E., Reisz, D., Ionita, M., and Lighezan, D. (2019). Migraine without Aura and Subclinical Atherosclerosis in Young Females: Is Gut Microbiota to Blame?. Medicina, 55.","DOI":"10.3390\/medicina55120786"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sanchez-Rodriguez, E., Egea-Zorrilla, A., Plaza-D\u00edaz, J., Arag\u00f3n-Vela, J., Mu\u00f1oz-Quezada, S., Tercedor-S\u00e1nchez, L., and Abadia-Molina, F. (2020). The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients, 12.","DOI":"10.3390\/nu12030605"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Saltzman, E.T., Palacios, T., Thomsen, M., and Vitetta, L. (2018). Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00061"},{"key":"ref_54","first-page":"2037838","article-title":"Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases","volume":"2018","author":"Faintuch","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jhep.2011.02.035","article-title":"DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH","volume":"55","author":"Dostert","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12938\/bmfh.18-032","article-title":"The role of gut microbiota in non-alcoholic fatty liver disease: Pathways of mechanisms","volume":"38","author":"Jasirwan","year":"2019","journal-title":"Biosci. Microbiota Food Health"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","article-title":"Gut microbiome in HCC\u2014Mechanisms, diagnosis and therapy","volume":"72","author":"Schwabe","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fendo.2019.00611","article-title":"Gut Dysfunction and Non-alcoholic Fatty Liver Disease","volume":"10","author":"Grabherr","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cld.1010","article-title":"The Influence of the Microbiome on NAFLD and NASH","volume":"17","author":"Albhaisi","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.2147\/IJGM.S350104","article-title":"Gallstone Disease and Bacterial Metabolic Performance of Gut Microbiota in Middle-Aged and Older Patients","volume":"15","author":"Georgescu","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJWH.S342882","article-title":"Dyspepsia and Gut Microbiota in Female Patients with Postcholecystectomy Syndrome","volume":"14","author":"Georgescu","year":"2022","journal-title":"Int. J. Womens Health"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gupta, H., Min, B.H., Ganesan, R., Gebru, Y.A., Sharma, S.P., Park, E., Won, S.M., Jeong, J.J., Lee, S.B., and Cha, M.G. (2022). Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030550"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/lt.25657","article-title":"Nonalcoholic Steatohepatitis After Liver Transplantation","volume":"26","author":"Cotter","year":"2020","journal-title":"Liver Transpl."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.12998\/wjcc.v9.i19.4980","article-title":"Liver injury in COVID-19: Known and unknown","volume":"9","author":"Zhou","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rahimmanesh, I., Shariati, L., Dana, N., Esmaeili, Y., Vaseghi, G., and Haghjooy Javanmard, S. (2021). Cancer Occurrence as the Upcoming Complications of COVID-19. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.813175"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biochi.2023.05.014","article-title":"Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent?","volume":"213","author":"Jahankhani","year":"2023","journal-title":"Biochimie"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Huang","year":"2020","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Saini, G., and Aneja, R. (2021). Cancer as a prospective sequela of long COVID-19. Bioessays, 43.","DOI":"10.1002\/bies.202000331"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"107633","DOI":"10.1016\/j.pharmthera.2020.107633","article-title":"Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy","volume":"215","author":"Ye","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_70","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Kazachenka, A., and Kassiotis, G. (2021). SARS-CoV-2-Host Chimeric RNA-Sequencing Reads Do Not Necessarily Arise From Virus Integration Into the Host DNA. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.676693"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kolly, P., and Dufour, J.F. (2016). Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics, 6.","DOI":"10.3390\/diagnostics6020022"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/hbsn.2017.06.04","article-title":"NAFLD-which patients should have hepatocellular carcinoma surveillance?","volume":"6","author":"Elcioglu","year":"2017","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/JHC.S159581","article-title":"Weighing the benefits of hepatocellular carcinoma surveillance against potential harms","volume":"6","author":"Geh","year":"2019","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21037\/hbsn.2019.08.08","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians","volume":"10","author":"Geh","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:54Z","timestamp":1760132454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["life14010025"],"URL":"https:\/\/doi.org\/10.3390\/life14010025","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,23]]}}}